Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SGMO
DateTimeSourceHeadlineSymbolCompany
26/02/202522:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
26/02/202522:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
26/02/202522:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
26/02/202522:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
26/02/202522:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
06/02/202513:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
06/02/202513:05Business WireSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety ProfileNASDAQ:SGMOSangamo Therapeutics Inc
24/01/202521:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
24/01/202521:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
24/01/202521:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
24/01/202521:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
24/01/202521:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
30/12/202421:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
30/12/202421:15Business WireSangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene FitelparvovecNASDAQ:SGMOSangamo Therapeutics Inc
19/12/202407:30PR Newswire (US)Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological DiseasesNASDAQ:SGMOSangamo Therapeutics Inc
19/12/202407:30Business WireSangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological DiseasesNASDAQ:SGMOSangamo Therapeutics Inc
26/11/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
26/11/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
26/11/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
26/11/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
26/11/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
20/11/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SGMOSangamo Therapeutics Inc
19/11/202421:15Business WireSangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic PainNASDAQ:SGMOSangamo Therapeutics Inc
12/11/202422:25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SGMOSangamo Therapeutics Inc
12/11/202422:24Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SGMOSangamo Therapeutics Inc
12/11/202421:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGMOSangamo Therapeutics Inc
12/11/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
12/11/202421:01Business WireSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
04/11/202421:15Business WireSangamo Therapeutics Announces Third Quarter 2024 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
28/10/202420:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SGMO